Biogen Inc. (BIIB) Shares Bought by Buckingham Capital Management Inc.
Buckingham Capital Management Inc. lifted its holdings in Biogen Inc. (NASDAQ:BIIB) by 13.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,723 shares of the biotechnology company’s stock after purchasing an additional 318 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Biogen were worth $853,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Pathstone Family Office LLC bought a new stake in Biogen in the 1st quarter valued at approximately $102,000. Prentiss Smith & Co. Inc. lifted its stake in Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 50 shares in the last quarter. Atlantic Trust LLC bought a new stake in Biogen in the 2nd quarter valued at approximately $114,000. Independent Portfolio Consultants Inc. lifted its stake in Biogen by 93.2% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 219 shares in the last quarter. Finally, Massey Quick Simon & CO. LLC lifted its stake in Biogen by 84.8% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 195 shares in the last quarter. Institutional investors and hedge funds own 88.35% of the company’s stock.
Biogen Inc. (NASDAQ:BIIB) traded up $3.70 during midday trading on Friday, reaching $313.98. The company had a trading volume of 731,700 shares, compared to its average volume of 1,512,280. Biogen Inc. has a fifty-two week low of $244.28 and a fifty-two week high of $348.84. The firm has a market capitalization of $66,460.00, a PE ratio of 14.37, a P/E/G ratio of 1.94 and a beta of 0.72. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.
Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.70 by $0.61. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the firm posted $5.19 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. sell-side analysts predict that Biogen Inc. will post 22.03 earnings per share for the current year.
A number of equities research analysts have recently issued reports on BIIB shares. Bank of America Corporation upped their price objective on Biogen from $358.00 to $365.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Citigroup Inc. cut Biogen from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. Piper Jaffray Companies reiterated an “overweight” rating and set a $390.00 price objective on shares of Biogen in a research note on Monday, October 23rd. Stifel Nicolaus upgraded Biogen from a “hold” rating to a “buy” rating and upped their price objective for the stock from $300.00 to $415.00 in a research note on Tuesday, October 17th. Finally, Mizuho upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $319.00 to $400.00 in a research note on Tuesday, October 17th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $341.89.
COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/17/biogen-inc-biib-shares-bought-by-buckingham-capital-management-inc.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.